4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study

A. M. Carella, G. Santini, M. Martinengo, D. Giordano, S. Nati, A. Congiu, R. Cerri, M. Risso, E. Damasio, E. Rossi

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Twenty-five adults with previously treated acute leukemia were treated with 4-demethoxydaunorubicin (Idarubicin) with a daily dose of 8 mg/m2 for 3 days intravenously. Complete remission was achieved in 3 of 18 patients with acute nonlymphatic leukemia (ANLL) and 2 of 6 with lymphoblastic leukemia. Complete remissions were observed in two of eight ANLL patients refractory to cytarabine, anthracycline, and m-Amsa (amsacrine), indicating a lack of cross-resistance between these drugs and Idarubicin. The median duration of remission was 8 weeks. The main major toxicity of Idarubicin therapy, severe myelosuppression, cannot be considered a toxic effect because it was desired in this case list. Our preliminary results indicate that Idarubicin has significant activity against refractory adult acute leukemia.

Original languageEnglish
Pages (from-to)1452-1454
Number of pages3
JournalCancer
Volume55
Issue number7
DOIs
Publication statusPublished - 1985

Fingerprint

Idarubicin
Leukemia
Amsacrine
Poisons
Anthracyclines
Cytarabine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Resistance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study. / Carella, A. M.; Santini, G.; Martinengo, M.; Giordano, D.; Nati, S.; Congiu, A.; Cerri, R.; Risso, M.; Damasio, E.; Rossi, E.

In: Cancer, Vol. 55, No. 7, 1985, p. 1452-1454.

Research output: Contribution to journalArticle

Carella, AM, Santini, G, Martinengo, M, Giordano, D, Nati, S, Congiu, A, Cerri, R, Risso, M, Damasio, E & Rossi, E 1985, '4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study', Cancer, vol. 55, no. 7, pp. 1452-1454. https://doi.org/10.1002/1097-0142(19850401)55:7<1452::AID-CNCR2820550705>3.0.CO;2-D
Carella, A. M. ; Santini, G. ; Martinengo, M. ; Giordano, D. ; Nati, S. ; Congiu, A. ; Cerri, R. ; Risso, M. ; Damasio, E. ; Rossi, E. / 4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study. In: Cancer. 1985 ; Vol. 55, No. 7. pp. 1452-1454.
@article{8cb2992e0ba64c958a3845ee01525cc8,
title = "4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study",
abstract = "Twenty-five adults with previously treated acute leukemia were treated with 4-demethoxydaunorubicin (Idarubicin) with a daily dose of 8 mg/m2 for 3 days intravenously. Complete remission was achieved in 3 of 18 patients with acute nonlymphatic leukemia (ANLL) and 2 of 6 with lymphoblastic leukemia. Complete remissions were observed in two of eight ANLL patients refractory to cytarabine, anthracycline, and m-Amsa (amsacrine), indicating a lack of cross-resistance between these drugs and Idarubicin. The median duration of remission was 8 weeks. The main major toxicity of Idarubicin therapy, severe myelosuppression, cannot be considered a toxic effect because it was desired in this case list. Our preliminary results indicate that Idarubicin has significant activity against refractory adult acute leukemia.",
author = "Carella, {A. M.} and G. Santini and M. Martinengo and D. Giordano and S. Nati and A. Congiu and R. Cerri and M. Risso and E. Damasio and E. Rossi",
year = "1985",
doi = "10.1002/1097-0142(19850401)55:7<1452::AID-CNCR2820550705>3.0.CO;2-D",
language = "English",
volume = "55",
pages = "1452--1454",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - 4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study

AU - Carella, A. M.

AU - Santini, G.

AU - Martinengo, M.

AU - Giordano, D.

AU - Nati, S.

AU - Congiu, A.

AU - Cerri, R.

AU - Risso, M.

AU - Damasio, E.

AU - Rossi, E.

PY - 1985

Y1 - 1985

N2 - Twenty-five adults with previously treated acute leukemia were treated with 4-demethoxydaunorubicin (Idarubicin) with a daily dose of 8 mg/m2 for 3 days intravenously. Complete remission was achieved in 3 of 18 patients with acute nonlymphatic leukemia (ANLL) and 2 of 6 with lymphoblastic leukemia. Complete remissions were observed in two of eight ANLL patients refractory to cytarabine, anthracycline, and m-Amsa (amsacrine), indicating a lack of cross-resistance between these drugs and Idarubicin. The median duration of remission was 8 weeks. The main major toxicity of Idarubicin therapy, severe myelosuppression, cannot be considered a toxic effect because it was desired in this case list. Our preliminary results indicate that Idarubicin has significant activity against refractory adult acute leukemia.

AB - Twenty-five adults with previously treated acute leukemia were treated with 4-demethoxydaunorubicin (Idarubicin) with a daily dose of 8 mg/m2 for 3 days intravenously. Complete remission was achieved in 3 of 18 patients with acute nonlymphatic leukemia (ANLL) and 2 of 6 with lymphoblastic leukemia. Complete remissions were observed in two of eight ANLL patients refractory to cytarabine, anthracycline, and m-Amsa (amsacrine), indicating a lack of cross-resistance between these drugs and Idarubicin. The median duration of remission was 8 weeks. The main major toxicity of Idarubicin therapy, severe myelosuppression, cannot be considered a toxic effect because it was desired in this case list. Our preliminary results indicate that Idarubicin has significant activity against refractory adult acute leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0021950710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021950710&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19850401)55:7<1452::AID-CNCR2820550705>3.0.CO;2-D

DO - 10.1002/1097-0142(19850401)55:7<1452::AID-CNCR2820550705>3.0.CO;2-D

M3 - Article

C2 - 3856461

AN - SCOPUS:0021950710

VL - 55

SP - 1452

EP - 1454

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -